Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast

HHormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), impacting current treatment of nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer (HSPC). Continued development of the hormonal therapies, plus the development of targeted agents (e.g., Janssen / GlaxoSmithKline’s Zejula, Pfizer’s Talzenna, AstraZeneca’s capivasertib), antibody-drug conjugates (MacroGenics’ vobramitamab duocarmazine), and novel prostate-specific membrane antigen (PSMA)-targeted radioligands (e.g., Novartis’s 177Lu-PSMA-617, Telix’s 77Lu-DOTA-rosopatamab, POINT Biopharma’s 177Lu-PNT2002), will drive robust market growth over the 2022-2032 forecast period.

QUESTIONS QUESTIONS ANSWERED

• What are the sizes of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates change over time?
• What are the key drivers and constraints in the prostate cancer market, and how will the major markets evolve over the 10-year forecast period?
• What is the current state of treatment for prostate cancer? What are interviewed experts’ insights on these treatment options?
• What is the clinical and commercial potential of late-phase pipeline products, and what will be their likely positioning and uptake in the market?

PRODUCTPRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), impacting current treatment algorithms for nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer (HSPC). Some patients with mCRPC are receiving triple combinations of current therapies. The dynamic late-phase pipeline mostly focuses on mCRPC and comprises a plethora of targeted agents (e.g., Janssen / GlaxoSmithKline’s Zejula, Pfizer’s Talzenna, Roche’s ipatasertib, AstraZeneca’s capivasertib) and novel prostate-specific membrane antigen (PSMA)-targeted radioligands (e.g., Novartis’s 177Lu-PSMA-617, Telix’s 77Lu-DOTA–rosopatamab, POINT Biopharma’s 177Lu-PNT2002). These agents will likely contribute to robust market growth over the 2021-2031 forecast period.QUESTIONS ANSWEREDPRODUCT DESCRIPTIONDisease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.SOLUTION ENHANCEMENTWhat are the sizes of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates change over time?What are the key drivers and constraints in the prostate cancer therapy market, and how will the major markets evolve over the 10-year forecast period?What is the current state of treatment for prostate cancer? What are interviewed experts’ insights on these treatment options?What is the clinical and commercial potential of late-phase pipeline products, and what will their positioning and uptake in the market be?Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.